Coty: Q1 earnings down sharply as expected, slightly more optimistic guidance for Q2|NIH attempts risky return to primary market|Sappi: EBITDA plummets in Q4 and the situation is unlikely to improve in the short term|Worldline presents its transformation plan and plans a capital increase of € 500m|Air Baltic: a new liquidity injection seems unavoidable|
Coty : Résultats T1 en net repli comme attendu, guidance légèrement plus optimiste pour le T2|NIH tente un retour risqué sur le marché primaire|Sappi : l’EBITDA s’effondre au T4 et la situation ne devrait pas s’arranger à court-terme|Worldline présente son plan de transformation et compte réaliser une augmentation de capital de 500 m EUR|Air Baltic: a new liquidity injection seems unavoidable|
Avolta: Q3 sales and EBITDA came in a shade below expectations, but cash generation exceeded expectations. Faster growth rate in North America in October.|Constellium: Results ahead of expectations, good Q4 expected, and guidance upgraded once again|Eramet : Q3 25 revenue lower than expected|Finnair: Guidance range tightened downwards amid higher costs and weaker demand|
Avolta : un T3 un peu en-dessous des attentes sur le CA et l’Ebitda mais meilleure sur la génération de cash. Accélération de la croissance en octobre en Amérique du Nord.|Constellium: Results ahead of expectations, good Q4 expected, and guidance upgraded once again|Eramet : CA T3 25 plus faible que prévu|Finnair: Guidance range tightened downwards amid higher costs and weaker demand|
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.